Medtronic’s 780G – Finally! – Gets FDA Approval
Executive Summary
Earlier than expected, but still after a more than three year wait, the company has obtained FDA approval for its flagship insulin delivery system.
You may also be interested in...
JPM 2024 Roundup: Abbott And Medtronic Push Diabetes Tech, Edwards Updates Tricuspid Progress, Shockwave Bets On R&D
Medtech Insight covered the major announcements from medtech companies during the J.P. Morgan Healthcare Conference in early January. Here are a few more highlights from companies that may not have made the headlines but will, no doubt, make noise in 2024.
An Insu-litigious Moment In The Patch Pump World
Insulet and EOFlow have been locked in a legal dispute for more than two months now, however it seems EOFlow may be on the back foot, after having an injunction made against it. This could have major implications for the wider diabetes sector, as a whole.
‘Closest To What The Pancreas Would Actually Do’: Medtronic Diabetes Execs On Marketing Plans For MiniMed 780G
In this third Exec Chat with leaders at major diabetes companies that presented at ADA’s Scientific Sessions 2023, Medtech Insight interviewed Medtronic diabetes business leaders Ali Dianaty and Jennifer McVean about the company’s marketing strategy for the recently launched MiniMed 780G with meal detection technology, plans for the Simplera disposable CGM, outlook on the consumer market, and more.